Skip to main navigation
Fate Therapeutics, Inc.
  • About Us
    • Overview
    • Leadership
    • Corporate Responsibility
  • Pipeline
    • Overview
    • Product Candidates
      • FT819
      • FT825
      • FT836
      • FT829
      • FT522
    • Early/Expanded Access Policy
  • Science
    • Our Cells of Interest
    • iPSC Platform
    • Manufacturing
    • Publications & Presentations
  • Patients
    • Our Commitment
    • Our Therapy
    • Autoimmune Disease
    • Cancer
    • Clinical Trials
  • Collaborations
  • Careers and Culture
    • The Fate Way
    • Join Our Team
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
    • Investors FAQs

Annual Reports and Proxies

Annual Reports

Title View
2024 Annual Report 3 MB
2024 Annual Report 3 MB
2023 Annual Report 8.2 MB
2023 Annual Report 8.2 MB
2022 Annual Report 2.3 MB
2022 Annual Report 2.3 MB
2021 Annual Report 2.1 MB
2021 Annual Report 2.1 MB
2020 Annual Report 1.1 MB
2020 Annual Report 1.1 MB
2019 Annual Report 1.1 MB
2019 Annual Report 1.1 MB
2018 Annual Report 9.6 MB
2018 Annual Report 9.6 MB
2017 Annual Report 4 MB
2017 Annual Report 4 MB
2016 Annual Report 4.7 MB
2016 Annual Report 4.7 MB
2015 Annual Report 998.1 KB
2015 Annual Report 998.1 KB
2014 Annual Report 7 MB
2014 Annual Report 7 MB

Financials & Filings submenus

  • SEC Filings
  • Annual Reports and Proxies

Proxy Statements

Filing date View
Apr 26, 2024 View HTML
0001193125-24-117981.pdf
0001193125-24-117981.xls
Apr 21, 2023 View HTML
0001193125-23-110475.pdf
0001193125-23-110475.xls
Apr 25, 2022 View HTML
0001193125-22-117516.pdf
0001193125-22-117516.xls
Apr 21, 2021 View HTML
0001193125-21-124699.pdf
0001193125-21-124699.xls

Shareholder Tools

Printed Materials
Email Alerts
Download Library
RSS News Feeds
Print Page
Share
Search

  • Facebook
  • LinkedIn
  • Twitter
  • RSS

© 2026 Fate Therapeutics | 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL

MENU
  • About Us
    • Overview
    • Leadership
    • Corporate Responsibility
  • Pipeline
    • Overview
    • Product Candidates
      • FT819
      • FT825
      • FT836
      • FT829
      • FT522
    • Early/Expanded Access Policy
  • Science
    • Our Cells of Interest
    • iPSC Platform
    • Manufacturing
    • Publications & Presentations
  • Patients
    • Our Commitment
    • Our Therapy
    • Autoimmune Disease
    • Cancer
    • Clinical Trials
  • Collaborations
  • Careers and Culture
    • The Fate Way
    • Join Our Team
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact